FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497461109> ?p ?o ?g. }

• W1497461109 abstract "With about 200 new products in the pipeline, recombinant human (rh) therapeutics are becoming the most dominant class of drugs. One of the reasons to create rh therapeutics was to avoid recognition by the immune system due to foreign origin. Nevertheless, rh therapeutics induced formation of anti-drug antibodies. Aggregation of the therapeutic protein became a major concern, directing the focus on an ancient mechanism of the immune system to recognize repetitive epitopes on pathogens and activation of a non-classical T-cell – B-cell pathway leading to a fast and efficient immune response. It was hypothesized that aggregated rh therapeutics mimic such repetitive epitope carrying pathogens, named T cell independent type 2 antigens. The thesis entitles ‘Immunological aspects of antibody formation against recombinant human therapeutics’ investigated the immunological mechanisms triggered after administration of aggregated rh therapeutics in transgenic mice immune tolerant for the therapeutic of interest. A three step approach was used: (I) Memory formation after administration of aggregated rh therapeutics?, (II) Is the response T cell independent?, (III) Do Marginal Zone B cells influence the immune response against rh therapeutics?. Two model therapeutics were used: (1) rh interferon beta, and (2) recombinant human interferon alpha. Both models showed the absence of memory formation after initial challenge and boost with both aggregated and non-aggregated rh drugs. In addition, a lack of neutralizing antibodies was observed. Though memory was absent, animals had an abundant pool of isotype switched antibodies, a sign for T cell dependency. And indeed, depletion of CD4+ T cells led to a complete abolishment of the antibody formation against aggregated therapeutic. Lastly, it could be shown that the depletion of marginal zone B cells influence the response against rh therapeutics. In conclusions, it was shown that the immune response directed against aggregated rh therapeutics is neither comparable to a classical nor to a T cell independent type 2 antigen. In addition, the presence of naturally occurring antibodies in human blood samples was investigated. It is hypothesized that patients having natural occurring antibodies against a rh therapeutic may be more susceptible to formation of anti-drug antibodies when treated with the rh therapeutic. The presence of naturally occurring antibodies against interferon alpha, beta and gamma and bone morphogenetic proteins 2 and 7 could be found in around 2% of individuals (n=400). Their influence on the immunogenicity of rh therapeutics need to be further explored." @default.
• W1497461109 created "2016-06-24" @default.
• W1497461109 creator A5010337176 @default.
• W1497461109 date "2010-12-06" @default.
• W1497461109 modified "2023-09-28" @default.
• W1497461109 title "Immunological aspects of antibody formation against recombinant human therapeutics" @default.
• W1497461109 cites W1506897962 @default.
• W1497461109 cites W1562476096 @default.
• W1497461109 cites W1568395771 @default.
• W1497461109 cites W1574724167 @default.
• W1497461109 cites W1579840516 @default.
• W1497461109 cites W1625396714 @default.
• W1497461109 cites W1834664928 @default.
• W1497461109 cites W1926100234 @default.
• W1497461109 cites W1963524859 @default.
• W1497461109 cites W1965286634 @default.
• W1497461109 cites W1967295501 @default.
• W1497461109 cites W1968558564 @default.
• W1497461109 cites W1968737533 @default.
• W1497461109 cites W1971979394 @default.
• W1497461109 cites W1973817062 @default.
• W1497461109 cites W1977357831 @default.
• W1497461109 cites W1979325667 @default.
• W1497461109 cites W1984283801 @default.
• W1497461109 cites W1985224319 @default.
• W1497461109 cites W1985279510 @default.
• W1497461109 cites W1985532156 @default.
• W1497461109 cites W2000744151 @default.
• W1497461109 cites W2005986251 @default.
• W1497461109 cites W2007228224 @default.
• W1497461109 cites W2008760839 @default.
• W1497461109 cites W2010764005 @default.
• W1497461109 cites W2011720055 @default.
• W1497461109 cites W2013708530 @default.
• W1497461109 cites W2015730831 @default.
• W1497461109 cites W2017759102 @default.
• W1497461109 cites W2021455647 @default.
• W1497461109 cites W2025687917 @default.
• W1497461109 cites W2025789524 @default.
• W1497461109 cites W2026761010 @default.
• W1497461109 cites W2027057014 @default.
• W1497461109 cites W2027644789 @default.
• W1497461109 cites W2029745420 @default.
• W1497461109 cites W2030920160 @default.
• W1497461109 cites W2031212349 @default.
• W1497461109 cites W2031889731 @default.
• W1497461109 cites W2032323981 @default.
• W1497461109 cites W2036463891 @default.
• W1497461109 cites W2041723098 @default.
• W1497461109 cites W2042126924 @default.
• W1497461109 cites W2046425987 @default.
• W1497461109 cites W2047575804 @default.
• W1497461109 cites W2048049691 @default.
• W1497461109 cites W2052240884 @default.
• W1497461109 cites W2053519499 @default.
• W1497461109 cites W2056616704 @default.
• W1497461109 cites W2059206445 @default.
• W1497461109 cites W2061659640 @default.
• W1497461109 cites W2062172468 @default.
• W1497461109 cites W2066566805 @default.
• W1497461109 cites W2069506532 @default.
• W1497461109 cites W2069644136 @default.
• W1497461109 cites W2070785786 @default.
• W1497461109 cites W2071095038 @default.
• W1497461109 cites W2073447892 @default.
• W1497461109 cites W2073547045 @default.
• W1497461109 cites W2078402861 @default.
• W1497461109 cites W2078523672 @default.
• W1497461109 cites W2080320061 @default.
• W1497461109 cites W2086437884 @default.
• W1497461109 cites W2088470932 @default.
• W1497461109 cites W2089304624 @default.
• W1497461109 cites W2090202059 @default.
• W1497461109 cites W2094312280 @default.
• W1497461109 cites W2095007655 @default.
• W1497461109 cites W2096397419 @default.
• W1497461109 cites W2100229044 @default.
• W1497461109 cites W2101086200 @default.
• W1497461109 cites W2110466329 @default.
• W1497461109 cites W2112453805 @default.
• W1497461109 cites W2113126462 @default.
• W1497461109 cites W2117553199 @default.
• W1497461109 cites W2118147754 @default.
• W1497461109 cites W2120389810 @default.
• W1497461109 cites W2125106761 @default.
• W1497461109 cites W2127946778 @default.
• W1497461109 cites W2128623893 @default.
• W1497461109 cites W2129012981 @default.
• W1497461109 cites W2131411928 @default.
• W1497461109 cites W2132754733 @default.
• W1497461109 cites W2133613306 @default.
• W1497461109 cites W2137203485 @default.
• W1497461109 cites W2138572955 @default.
• W1497461109 cites W2140022778 @default.
• W1497461109 cites W2142793548 @default.
• W1497461109 cites W2145736817 @default.
• W1497461109 cites W2146049783 @default.
• W1497461109 cites W2146891097 @default.
• W1497461109 cites W2149766132 @default.
• W1497461109 cites W2153717284 @default.

• next